10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $33M | -$353M | 0.0% | -1169.7% | -$484M | $99M | $222M |
| 2024 | $51M | -$283M | 0.0% | -647.1% | -$176M | $48M | $150M |
| 2023 | $37M | -$307M | 0.0% | -918.9% | -$330M | $0 | $127M |
| 2022 | $38M | -$267M | 0.0% | -736.8% | $432M | — | $206M |
| 2021 | $383M | $53M | 0.0% | 14.1% | -$282M | — | $148M |
| 2020 | $78M | -$123M | 0.0% | -159.0% | $108M | — | $173M |
| 2019 | $15M | -$85M | 0.0% | -591.4% | -$75M | — | $58M |
| 2018 | $8M | -$50M | 0.0% | -656.8% | -$47M | — | $71M |
| 2017 | — | -$53M | — | — | -$31M | — | $98M |
| 2016 | — | -$18M | — | — | -$17M | — | $65M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $7M | -$128M | 0.0% | -1914.3% | -$138M | $100M | $201M |
| Dec '25 | $11M | -$106M | 0.0% | -1036.4% | -$121M | $99M | $222M |
| Sep '25 | $6M | -$135M | 0.0% | -2366.7% | -$97M | $98M | $238M |
| Jun '25 | $8M | $0 | 0.0% | -100.0% | -$133M | $97M | $248M |
| Mar '25 | $8M | -$112M | 0.0% | -1525.0% | -$133M | $48M | $192M |
| Dec '24 | $23M | -$94M | 0.0% | -447.8% | -$101M | $48M | $150M |
| Sep '24 | $7M | -$92M | 0.0% | -1500.0% | $25M | $47M | $201M |
| Jun '24 | $11M | -$93M | 0.0% | -963.6% | -$94M | — | $156M |
| Mar '24 | $10M | -$4M | 0.0% | -160.0% | -$6M | — | $185M |
| Dec '23 | -$49M | -$81M | 0.0% | 185.7% | -$94M | $0 | $127M |
| Sep '23 | $32M | -$71M | 0.0% | -250.0% | -$73M | — | $184M |
| Jun '23 | $29M | -$75M | 0.0% | -286.2% | -$62M | — | $230M |
| Mar '23 | $25M | -$80M | 0.0% | -344.0% | -$101M | — | $238M |
| Dec '22 | $34M | -$67M | 0.0% | -217.6% | -$70M | — | $206M |
| Sep '22 | $33M | -$65M | 0.0% | -212.1% | -$83M | — | $218M |
| Jun '22 | $27M | -$67M | 0.0% | -255.6% | -$66M | — | $273M |
| Mar '22 | $18M | -$68M | 0.0% | -372.2% | $651M | — | $549M |
| Dec '21 | $355M | $280M | 0.0% | 79.2% | -$70M | — | $148M |
| Sep '21 | $9M | -$78M | 0.0% | -825.9% | -$62M | — | $179M |
| Jun '21 | $9M | -$76M | 0.0% | -804.7% | -$80M | — | $320M |
How the market has priced RCUS against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Arcus Biosciences, Inc.'s revenue has declined 15.8% per year. These are computed facts, not advice.
As of FY2025, Arcus Biosciences, Inc. reported $99M of total debt against $222M of cash; operating income covered interest expense -48.3×.
In FY2025, gross margin was —, operating margin -1169.7%, and net margin -1069.7%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.